Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/29261
Title: | Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats |
Authors: | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı. Hamurtekin, Emre Bağdaş, Deniz Gürun, M. Sibel AAG-8716-2019 8717648500 15062425700 55664349700 |
Keywords: | GABA receptors Nicotinic acetylcholine-receptors Alpha-7 nicotinic receptors Antinociception CDP-choline Opioid receptors Pain Morphine-induced antinociception Analgesic activity Agonists Release Antagonists Modulation Mechanisms Citicoline Diversity Neurosciences & neurology |
Issue Date: | 24-Apr-2007 |
Publisher: | Elsevier Ireland |
Citation: | Hamurtekin, E. vd. (2007). "Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats". Neuroscience Letters, 420(2), 116-121. |
Abstract: | Cytidine-5'-diphosphate choline (CDP-choline; citicoline) is an essential endogenous compound normally produced by the organism and is a source of cytidine and choline. Our recent studies on acute pain models demonstrate that intracerebroventricularly administered CDPcholine produces antinociception via supraspinal alpha-7 nicotinic acetylcholine receptors-mediated mechanism in rats. However, it remains to be elucidated which other supraspinal mechanisms are involved in the antinociceptive effect of CDP-choline. In this study, we investigated the role of the supraspinal opioidergic, GABAergic, alpha-adrenergic and serotonergic receptors in CDP-choline-induced antinociception. The antinociceptive effect of CDP-choline was evoked by the intracerebroventricular (i.c.v.) administration. Two different pain models were utilized: thermal paw withdrawal test and mechanical paw pressure test. The i.c.v. administration of CDP-choline (0.5, 1.0 and 2.0 mu mol) produced dose-dependent antinociception. Non-specific opioid receptor antagonist naloxone (10 mu g; i.c.v.) and GABA(B) receptor antagonist CGP-35348 (20 mu g; i.c.v.) pretreatments inhibited the antinociceptive effects of CDP-choline (1.0 mu mol; i.c.v.). In contrast, the alpha-1 adrenergic receptor antagonist prazosin (20 mu g; i.c.v.), alpha-2 adrenergic receptor antagonist yohimbine (30 mu g; i.c.v.) and non-specific scrotonin receptor antagonist methysergide (20 mu g; i.c.v.) pretreatments had no effect on CDP-choline-induced antinociception in the thermal paw withdrawal test and in the mechanical paw pressure test. Therefore, it can be postulated that i.c.v. administered CDP-choline exerts antinociceptive effect mediated by supraspinal opioid and GABAB receptors in acute pain models. Furthermore, supraspinal alpha-adrenergic and serotonergic receptors do not appear to be involved in the antinociceptive effect of CDP-choline. |
URI: | https://doi.org/10.1016/j.neulet.2007.04.058 https://www.sciencedirect.com/science/article/pii/S0304394007005095 http://hdl.handle.net/11452/29261 |
ISSN: | 0304-3940 1872-7972 |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.